Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage · HPV-Related Squamous Cell Carcinoma · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage · HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Brigham and Women's Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Jonathan Schoenfeld, MD, MPH) · jonathan_schoenfeld@dfci.harvard.edu · 617.632.5296Contact: Principal Investigator (Jonathan Schoenfeld, MD, MPH)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Jonathan D. Schoenfeld, MD, MPH) · jonathan_schoenfeld@dfci.harvard.edu · 617.632.5296Contact: Principal Investigator (Jonathan D. schoenfeld, MD)
Study leads
Jonathan D Schoenfeld, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute